Index -
P/E -
EPS (ttm) -2.74
Insider Own 2.56%
Shs Outstand 75.37M
Perf Week -1.69%
Market Cap 3.04B
Forward P/E -
EPS next Y -3.59
Insider Trans 0.00%
Shs Float 73.82M
Perf Month 2.58%
Income -199.06M
PEG -
EPS next Q -0.83
Inst Own 96.53%
Short Float 4.84%
Perf Quarter 7.10%
Sales 0.00M
P/S -
EPS this Y -14.34%
Inst Trans 1.08%
Short Ratio 8.79
Perf Half Y -7.59%
Book/sh 11.15
P/B 3.60
EPS next Y -15.06%
ROA -25.38%
Short Interest 3.57M
Perf Year 12.03%
Cash/sh 9.52
P/C 4.22
EPS next 5Y 8.90%
ROE -26.71%
52W Range 27.99 - 50.99
Perf YTD -12.83%
Dividend Est. -
P/FCF -
EPS past 5Y -10.87%
ROI -23.34%
52W High -21.26%
Beta 1.25
Dividend TTM -
Quick Ratio 23.27
Sales past 5Y 35.90%
Gross Margin -
52W Low 43.47%
ATR (14) 1.42
Dividend Ex-Date -
Current Ratio 23.27
EPS Y/Y TTM -9.82%
Oper. Margin 0.00%
RSI (14) 50.99
Volatility 3.24% 3.31%
Employees 259
Debt/Eq 0.01
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.07
Target Price 58.15
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -3.50%
Payout -
Rel Volume 0.77
Prev Close 40.79
Sales Surprise -
EPS Surprise -7.11%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 405.87K
Price 40.15
SMA20 0.60%
SMA50 -1.79%
SMA200 -4.63%
Trades
Volume 311,468
Change -1.57%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-04-24 Initiated
Citigroup
Buy
$62
Dec-08-23 Initiated
Robert W. Baird
Outperform
$63
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
Apr-25-23 Initiated
Cantor Fitzgerald
Overweight
$58
Dec-14-22 Initiated
Goldman
Buy
$60
Dec-12-22 Initiated
Cowen
Outperform
Nov-28-22 Initiated
Wells Fargo
Overweight
$50
Oct-19-22 Initiated
Raymond James
Outperform
$52
Aug-29-22 Initiated
BofA Securities
Buy
$45
Jul-21-22 Initiated
JP Morgan
Overweight
$55
Oct-28-21 Initiated
RBC Capital Mkts
Outperform
$43
Oct-02-20 Initiated
SVB Leerink
Outperform
$22
Jul-21-20 Initiated
Needham
Buy
$22
Jun-01-20 Resumed
Jefferies
Buy
$23
Mar-25-20 Initiated
Wedbush
Outperform
$23
Jan-08-20 Initiated
William Blair
Outperform
Sep-20-19 Initiated
Guggenheim
Buy
$25
Aug-08-18 Reiterated
Stifel
Buy
$9 → $15
Mar-13-17 Initiated
Jefferies
Buy
$13
Oct-21-16 Initiated
Stifel
Buy
$18
Show Previous Ratings
Sep-09-24 08:30AM
Sep-05-24 01:12AM
Sep-02-24 06:05PM
Aug-21-24 10:46AM
Aug-12-24 08:30AM
10:19AM
Loading…
Aug-09-24 10:19AM
Aug-08-24 09:59PM
04:26PM
(Associated Press Finance)
04:01PM
Aug-01-24 04:01PM
Jun-27-24 03:54PM
Jun-05-24 04:01PM
May-28-24 08:30AM
May-27-24 06:55PM
06:13PM
05:03PM
Loading…
May-10-24 05:03PM
12:56PM
08:17AM
07:29AM
May-09-24 08:57PM
04:29PM
04:17PM
(Associated Press Finance)
04:01PM
May-08-24 04:01PM
May-07-24 04:01PM
May-06-24 12:00PM
May-02-24 04:01PM
Apr-16-24 08:30AM
Apr-10-24 08:30AM
Apr-04-24 04:01PM
04:01PM
Loading…
Mar-12-24 04:01PM
Mar-08-24 11:55PM
Mar-05-24 04:01PM
Mar-02-24 08:37AM
Mar-01-24 08:35AM
Feb-29-24 04:34PM
04:13PM
(Associated Press Finance)
04:01PM
Feb-22-24 04:01PM
Feb-21-24 10:08PM
Jan-23-24 08:36AM
Jan-19-24 09:55AM
Jan-08-24 08:00AM
Jan-03-24 08:30AM
Dec-05-23 01:31PM
Dec-04-23 04:16PM
Dec-02-23 12:01PM
Nov-29-23 10:51PM
04:03PM
Nov-28-23 11:17AM
Nov-27-23 04:28PM
(Investor's Business Daily) +17.78%
12:19PM
(Associated Press Finance)
07:30AM
07:09AM
07:00AM
04:21AM
Nov-09-23 05:14PM
04:03PM
Nov-08-23 04:28PM
(Associated Press Finance)
04:01PM
Nov-01-23 04:01PM
Oct-31-23 02:58AM
Oct-09-23 04:15PM
Oct-06-23 08:30AM
Sep-14-23 04:01PM
Sep-12-23 04:30PM
Sep-04-23 08:30AM
Aug-31-23 10:16PM
04:01PM
Aug-29-23 10:21AM
Aug-11-23 09:55AM
Aug-09-23 05:15PM
04:09PM
04:01PM
08:03AM
Aug-08-23 04:01PM
Aug-02-23 04:01PM
Jul-23-23 11:44AM
Jun-06-23 04:35PM
May-31-23 04:01PM
May-11-23 04:01PM
May-09-23 05:15PM
04:13PM
04:01PM
May-04-23 10:00AM
03:52AM
May-03-23 04:01PM
May-02-23 04:01PM
10:01AM
Apr-24-23 08:00AM
Apr-21-23 04:01PM
Apr-18-23 08:15AM
Mar-22-23 04:01PM
Mar-06-23 01:07AM
Mar-04-23 07:48AM
Mar-02-23 05:31AM
Mar-01-23 05:25PM
04:01PM
Feb-22-23 04:01PM
Feb-08-23 04:01PM
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GAROFALO ELIZABETH A. Director Mar 08 '24 Option Exercise 18.56 3,500 64,960 3,500 Mar 11 08:09 PM GAROFALO ELIZABETH A. Director Mar 08 '24 Sale 45.69 2,092 95,583 0 Mar 11 08:09 PM ROBIN SHERRINGTON EVP, Strategy & Innovation Mar 07 '24 Option Exercise 9.85 8,641 85,114 16,824 Mar 08 05:31 PM ROBIN SHERRINGTON EVP, Strategy & Innovation Mar 07 '24 Sale 46.28 7,137 330,290 8,398 Mar 08 05:31 PM GANNON STEVEN Director Mar 07 '24 Sale 46.28 13,000 601,615 2,000 Mar 08 05:28 PM AZAB MOHAMMAD Director Dec 19 '23 Option Exercise 9.85 4,320 42,552 74,225 Dec 20 05:04 PM PATOU GARY Director Dec 13 '23 Option Exercise 9.55 14,402 137,487 29,951 Dec 15 05:38 PM PATOU GARY Director Dec 13 '23 Sale 39.29 11,380 447,085 23,573 Dec 15 05:38 PM PATOU GARY Director Dec 13 '23 Sale 41.05 7,598 311,898 4,902 Dec 15 05:38 PM
Index RUT
P/E -
EPS (ttm) -3.06
Insider Own 35.41%
Shs Outstand 97.87M
Perf Week 14.68%
Market Cap 537.98M
Forward P/E -
EPS next Y -2.10
Insider Trans -0.03%
Shs Float 64.46M
Perf Month 12.29%
Income -299.80M
PEG -
EPS next Q -0.80
Inst Own 77.37%
Short Float 11.16%
Perf Quarter 32.11%
Sales 0.00M
P/S -
EPS this Y 45.60%
Inst Trans -
Short Ratio 6.28
Perf Half Y -30.72%
Book/sh 5.71
P/B 0.94
EPS next Y 28.97%
ROA -40.33%
Short Interest 7.20M
Perf Year -45.28%
Cash/sh 6.36
P/C 0.85
EPS next 5Y -
ROE -43.79%
52W Range 3.36 - 10.70
Perf YTD -27.75%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -52.66%
52W High -49.65%
Beta 2.29
Dividend TTM -
Quick Ratio 7.86
Sales past 5Y 0.00%
Gross Margin -
52W Low 60.42%
ATR (14) 0.44
Dividend Ex-Date -
Current Ratio 7.86
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 59.10
Volatility 10.31% 8.17%
Employees 130
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.86
Target Price 11.40
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -222.51%
Payout -
Rel Volume 2.85
Prev Close 5.30
Sales Surprise -
EPS Surprise -10.26%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 1.15M
Price 5.39
SMA20 14.01%
SMA50 2.02%
SMA200 -9.42%
Trades
Volume 3,268,593
Change 1.70%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Downgrade
H.C. Wainwright
Buy → Neutral
$18 → $6
Jul-08-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$13
Dec-13-23 Initiated
Wells Fargo
Equal Weight
$11
Dec-08-23 Initiated
Citigroup
Neutral
$8
Sep-13-23 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$19
Sep-05-23 Initiated
H.C. Wainwright
Buy
$44
May-30-23 Initiated
TD Cowen
Outperform
May-30-23 Initiated
Piper Sandler
Overweight
$68
May-30-23 Initiated
Morgan Stanley
Overweight
May-30-23 Initiated
Jefferies
Buy
$31
Sep-19-24 07:00AM
Sep-12-24 01:30AM
Sep-10-24 07:00AM
Aug-22-24 07:00AM
Aug-13-24 04:00PM
03:37AM
Loading…
03:37AM
Aug-06-24 04:30PM
Jun-05-24 07:00AM
May-29-24 07:00AM
May-15-24 11:54AM
May-09-24 08:01AM
08:00AM
Apr-29-24 04:05PM
Mar-28-24 10:53PM
04:05PM
04:01PM
Loading…
Mar-27-24 04:01PM
Mar-21-24 11:12AM
Mar-20-24 07:00AM
12:39AM
Mar-11-24 10:04AM
(FierceBiotech.com) +10.96%
08:02AM
08:00AM
Feb-15-24 04:05PM
Jan-10-24 11:30AM
Jan-04-24 09:56AM
Jan-01-24 09:35AM
Dec-27-23 10:45AM
Dec-20-23 04:30PM
Dec-19-23 12:13AM
Dec-18-23 04:14PM
09:25PM
Loading…
Dec-12-23 09:25PM
Dec-11-23 09:35AM
Dec-04-23 03:00PM
08:00AM
Nov-30-23 04:30PM
Nov-28-23 05:55PM
(GlobeNewswire) -32.41%
+8.16%
01:44PM
07:24AM
Nov-27-23 09:09PM
04:30PM
Nov-20-23 11:01AM
Nov-16-23 06:42PM
04:11PM
Nov-07-23 05:11PM
04:05PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
(The Wall Street Journal)
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Becker Daniel J. Director Jul 17 '24 Sale 6.86 1 7 2,999 Jul 19 06:18 PM Lin Shao-Lee Chief Executive Officer Apr 01 '24 Sale 6.63 9,961 66,024 1,577,374 Apr 03 06:18 PM Lin Shao-Lee Chief Executive Officer Feb 20 '24 Sale 7.60 15,701 119,403 1,587,335 Feb 22 07:04 PM Lin Shao-Lee Chief Executive Officer Jan 02 '24 Sale 7.41 10,691 79,188 1,603,036 Jan 04 06:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite